Notice to Clarify Reference to Centers for Disease Control and Prevention Report in RFA-AI-17-026 “Partnerships for Countermeasures Against Select Pathogens (R01)"

Notice Number: NOT-AI-17-041

Key Dates
Release Date:  September 12, 2017

Related Announcements
RFA-AI-17-026

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to provide the hyperlink to the Centers for Disease Control and Prevention’s Antibiotic Resistance Threats in the United States, 2013 report referenced in the “Therapeutics” category under the Research Goals, Objectives, and Scope section of RFA-AI-17-026 , “Partnerships for Countermeasures Against Select Pathogens (R01).”

Part 2. Section I. Funding Opportunity Description

Research Goals, Objectives, and Scope

 

Therapeutics

Current Language:

Antimicrobial-Resistant Bacteria/Fungi

This initiative will support development of new or improved therapeutics for select pathogens for which drug resistance poses a significant public health concern. Responsive applications must target at least one pathogen listed in the Centers for Disease Control and Prevention’s Antibiotic Resistance Threats in the United States, 2013 report. Projects focused on drug-resistant Mycobacterium tuberculosis are limited to development and/or evaluation of therapeutic entities that are not currently licensed for another indication (that is, projects focused on repurposed drugs are excluded). Antibacterial categories supported by this FOA include, but are not limited to, narrow-spectrum drugs, broad-spectrum drugs, innovative therapeutic approaches/strategies, drugs targeting novel mechanisms, or adjunctive therapeutics.

Revised Language:
Antimicrobial-Resistant Bacteria/Fungi

This initiative will support development of new or improved therapeutics for select pathogens for which drug resistance poses a significant public health concern. Responsive applications must target at least one pathogen listed in the Centers for Disease Control and Prevention’s Antibiotic Resistance Threats in the United States, 2013 report (https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf).  Projects focused on drug-resistant Mycobacterium tuberculosis are limited to development and/or evaluation of therapeutic entities that are not currently licensed for another indication (that is, projects focused on repurposed drugs are excluded). Antibacterial categories supported by this FOA include, but are not limited to, narrow-spectrum drugs, broad-spectrum drugs, innovative therapeutic approaches/strategies, drugs targeting novel mechanisms, or adjunctive therapeutics.

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Michael Schaefer, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID) 
Telephone: 240-627-3364
Email: mschaefer@niaid.nih.gov